Intrexon Corp (NYSE:XON) gapped down before the market opened on Friday . The stock had previously closed at $16.78, but opened at $15.39. Intrexon shares last traded at $15.05, with a volume of 3024986 shares traded.
Several research analysts have weighed in on XON shares. Zacks Investment Research lowered shares of Intrexon from a “buy” rating to a “hold” rating in a research note on Monday, July 16th. Stifel Nicolaus started coverage on shares of Intrexon in a research note on Tuesday, July 17th. They set a “buy” rating and a $72.00 target price for the company. Finally, Bank of America lowered shares of Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price objective for the company. in a research note on Monday, July 16th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Hold” and an average target price of $36.00.
The company has a quick ratio of 1.93, a current ratio of 2.16 and a debt-to-equity ratio of 0.01.
Institutional investors have recently modified their holdings of the stock. Peregrine Capital Management LLC raised its holdings in Intrexon by 15.7% during the second quarter. Peregrine Capital Management LLC now owns 711,266 shares of the biotechnology company’s stock worth $9,915,000 after purchasing an additional 96,393 shares in the last quarter. Wellington Shields & Co. LLC acquired a new position in shares of Intrexon in the 1st quarter valued at $4,691,000. Northern Trust Corp increased its holdings in shares of Intrexon by 9.7% in the 1st quarter. Northern Trust Corp now owns 411,324 shares of the biotechnology company’s stock valued at $6,305,000 after acquiring an additional 36,508 shares during the period. Chessman Wealth Strategies RIA acquired a new position in shares of Intrexon in the 2nd quarter valued at $205,000. Finally, Private Advisor Group LLC acquired a new position in shares of Intrexon in the 1st quarter valued at $375,000. Institutional investors own 83.64% of the company’s stock.
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Article: Outstanding Shares, Buying and Selling Stocks
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.